- Research works
- 25 ▲ 96% vs 2013–17
- Citations
- 550 21.9 per fractional work
- Top-10% rate
- 11.5% record average 16.5%
- Open access
- 78% world 28%
Not ranked overall: JINIS Biopharmaceuticals (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 28.2×. Every wedge is a field page.
- Veterinary 28.2×
- Nursing 7.8×
- Biochemistry, Genetics and Molecular Biology 5.0×
- Agricultural and Biological Sciences 3.6×
- Dentistry 3.2×
- Business, Management and Accounting 1.4×
- Medicine 1.4×
- Environmental Science 0.9×
- Immunology and Microbiology 0.7×
- Computer Science 0.6×
- Health Professions 0.6×
- Materials Science 0.3×
- Engineering 0.2×
- Social Sciences 0.1×
Which keywords describe research at JINIS Biopharmaceuticals (South Korea)?
By fractional works in all years, weighted toward what it does more of than the world: Inflammation, Oxidative Stress, Cancer Therapy, Genome Engineering, RNA-Guided, Metabolism, Metabolic Syndrome and Neurodegeneration.
- Gut Microbiota
- Cancer
- Metabolism
- Genome Engineering
- Oxidative Stress
- Inflammation
- Cancer Therapy
- Metabolic Syndrome
- RNA-Guided
- Epidemiology
- Neurodegeneration
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 11 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 11 words, with their numbers
- Inflammation2▲ 4.3×13 topics
- Oxidative Stress2▲ 4.9×8 topics
- Cancer Therapy2▲ 9.4×4 topics
- Genome Engineering1▲ 86×1 topic
- Metabolic Syndrome1▲ 6.0×5 topics
- Metabolism1▲ 7.7×6 topics
- RNA-Guided1▲ 86×1 topic
- Cancer1▲ 3.1×8 topics
- Epidemiology1◆ 1.05×9 topics
- Gut Microbiota1▲ 13×2 topics
- Neurodegeneration1▲ 15×5 topics
Which research topics does JINIS Biopharmaceuticals (South Korea) publish most on?
By volume in 2022–2025: CRISPR and Genetic Engineering, Animal Behavior and Welfare Studies, Plant tissue culture and regeneration and Chromosomal and Genetic Variations.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CRISPR and Genetic Engineering Molecular Biology 1 works
- 2 Animal Behavior and Welfare Studies Small Animals 0 works
- 3 Plant tissue culture and regeneration Molecular Biology 0 works
- 4 Chromosomal and Genetic Variations Plant Science 0 works
- 5 Platelet Disorders and Treatments Hematology 0 works
- 6 Banking, Crisis Management, COVID-19 Impact General Agricultural and Biological Sciences 0 works
- 7 Heparin-Induced Thrombocytopenia and Thrombosis Surgery 0 works
- 8 Corporate Finance and Governance Accounting 0 works
- 9 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
- 10 Business and Economic Development Management, Monitoring, Policy and Law 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has JINIS Biopharmaceuticals (South Korea)'s research output changed?
Output in 2018–2022 was 96% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Jeonju
- Jeonbuk National University
- Rural Development Administration
- Jeonbuk National University Hospital
- Jeonju University
- Jesus University
- Woosuk University
- Presbyterian Medical Center
- Jeonju National University of Education
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.